OrfaliRLAokiV. Blockage of the IL-31 pathway as a potential target therapy for atopic dermatitis. Pharmaceutics. 2023;15(2):577. doi:10.3390/pharmaceutics15020577
2.
ShaoYWangDZhuY, et al. Molecular mechanisms of pruritus in prurigo nodularis. Front Immunol. 2023;14:1301817. doi:10.3389/fimmu.2023.1301817
3.
KwatraSGYosipovitchGLegatFJ, et al. Phase 3 trial of nemolizumab in patients with prurigo nodularis. N Engl J Med. 2023;389(17):1579-1589. doi:10.1056/NEJMoa2301333
4.
Guttman-YasskyEPavelABDiazA, et al. Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers. J Allergy Clin Immunol. 2022;149(4):1318-1328. doi:10.1016/j.jaci.2021.10.036
5.
StänderSKwatraSGSilverbergJI, et al. Early itch response with abrocitinib is associated with later efficacy outcomes in patients with moderate-to-severe atopic dermatitis: subgroup analysis of the randomized phase III JADE COMPARE trial. Am J Clin Dermatol. 2023;24(1):97-107. doi:10.1007/s40257-022-00738-4
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
